Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.
North America is the largest consumption market of Pneumococcal Vaccine with sales market share nearly 40% in 2015.
The second place is Europe, following North America with sales market share over 18% in 2016. Asia-Pacific is another important market of Pneumococcal Vaccine, enjoy nearly 16% sales market share in 2013, but the consumption experienced a sharp decrease due to approval of government departments in last few years.
Market Analysis and Insights: Global Pneumococcal Vaccine Market
The global Pneumococcal Vaccine market was valued at US$ 7200.2 in 2020 and will reach US$ 7688.7 million by the end of 2027, growing at a CAGR of 1.1% during 2022-2027.
Global Pneumococcal Vaccine Scope and Market Size
The global Pneumococcal Vaccine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Pneumococcal Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
PPSV 23
PCV 7/13
PCV 10
Segment by Application
Child
Adult
The Pneumococcal Vaccine market is analysed and market size information is provided by regions (countries). Segment by Application, the Pneumococcal Vaccine market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Pfizer
GSK
MSD
Sanofipasteur
CDIBP
North America is the largest consumption market of Pneumococcal Vaccine with sales market share nearly 40% in 2015.
The second place is Europe, following North America with sales market share over 18% in 2016. Asia-Pacific is another important market of Pneumococcal Vaccine, enjoy nearly 16% sales market share in 2013, but the consumption experienced a sharp decrease due to approval of government departments in last few years.
Market Analysis and Insights: Global Pneumococcal Vaccine Market
The global Pneumococcal Vaccine market was valued at US$ 7200.2 in 2020 and will reach US$ 7688.7 million by the end of 2027, growing at a CAGR of 1.1% during 2022-2027.
Global Pneumococcal Vaccine Scope and Market Size
The global Pneumococcal Vaccine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Pneumococcal Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
PPSV 23
PCV 7/13
PCV 10
Segment by Application
Child
Adult
The Pneumococcal Vaccine market is analysed and market size information is provided by regions (countries). Segment by Application, the Pneumococcal Vaccine market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Pfizer
GSK
MSD
Sanofipasteur
CDIBP
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
